An Open Phase 2 Trial to Evaluate Safety of a Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs VCL CB01 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 31 Jul 2013 New trial record